Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.

Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ.

Breast Cancer Res. 2007;9(5):R65.

2.

Triple-negative breast cancer: clinical features and patterns of recurrence.

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34.

3.

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.

Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD.

BMC Cancer. 2007 Jul 24;7:134.

4.
5.

Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysis.

Sherman ME, Rimm DL, Yang XR, Chatterjee N, Brinton LA, Lissowska J, Peplonska B, Szeszenia-Dabrowska N, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Kalaylioglu Z, Harigopal M, Charrette L, Falk RT, Richesson D, Anderson WF, Hewitt SM, García-Closas M.

Int J Cancer. 2007 Sep 1;121(5):1079-85.

6.

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.

Clin Cancer Res. 2007 Apr 15;13(8):2329-34.

8.

Differences in risk factors for breast cancer molecular subtypes in a population-based study.

Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, García-Closas M.

Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):439-43.

9.

Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers.

Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA, Kuperwasser C.

Cancer Res. 2007 Mar 1;67(5):2062-71.

10.

Prognostic markers in triple-negative breast cancer.

Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO.

Cancer. 2007 Jan 1;109(1):25-32.

11.

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.

Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L.

Breast Cancer Res. 2006;8(6):R66.

12.

Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.

Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D.

J Clin Oncol. 2006 Dec 20;24(36):5652-7. Epub 2006 Nov 20.

13.

Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis.

Kahlenborn C, Modugno F, Potter DM, Severs WB.

Mayo Clin Proc. 2006 Oct;81(10):1290-302.

PMID:
17036554
15.

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM.

Mod Pathol. 2006 Feb;19(2):264-71.

16.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N.

N Engl J Med. 2005 Oct 20;353(16):1673-84.

17.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team.

N Engl J Med. 2005 Oct 20;353(16):1659-72.

18.

Etiology of hormone receptor-defined breast cancer: a systematic review of the literature.

Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME.

Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1558-68. Review.

19.

Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup.

Cotterchio M, Kreiger N, Theis B, Sloan M, Bahl S.

Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1053-60.

20.

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, Trudel M, Akslen LA.

J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5.

Items per page

Supplemental Content

Write to the Help Desk